news-med.jpg

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development

Hamburg, Germany, 03 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research ...

Topics: Corporate, Sanofi, Evotec, infectious diseases Read More

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a ...

Topics: Corporate, Sanofi, Evotec, infectious diseases Read More